Results 161 to 170 of about 530,731 (290)

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

British Journal of Haematology, EarlyView.
Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, Junling Zhuang   +15 more
wiley   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann, Sarah Flossdorf, Julius Keyl, Theo Leitner, Cyrus Khandanpour, Markus Maulhardt, Evgenii Shumilov, Matthias Stelljes, Lisa Leypoldt, Marie Harzer, Christoph Schaefers, Francis Ayuketang Ayuk, Bastian von Tresckow, Amelie Boquoi, Thomas Schroeder, Hans Christian Reinhardt, Christine Hanoun   +16 more
wiley   +1 more source

JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell-Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers. [PDF]

Mol Cancer Ther
Smans K, Nesspor T, De Breucker S, van Heerde E, Valckx A, Van Slycken N, Sproesser K, Cypert BM, Packman K, Chu G, Fisher J, Mazzanti N, Petley T, Chan W, Del Rosario B, Liu T, Ember S, Shaffer PL, Clawson JS, Bauml JM, Moores S, Laquerre S, Gavine PR.   +22 more
europepmc   +1 more source

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real‐world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre‐CAR T era

British Journal of Haematology, EarlyView.
Stéphanie Guidez, Aurélien Belot, Fanny Cherblanc, Bastien Lesné, Sylvain Carras, Catherine Thieblemont, Fontanet Bijou, Cédric Rossi, Luc Mathieu Fornecker, Jehan Dupuis, Krimo Bouabdallah, Ludovic Fouillet, Adrien Chauchet, Benoit Tessoulin, Loic Ysebaert, Alice Pauc, Pascale Cony‐Makhoul, Remy Gressin, Gaelle Laboure, Antoine Bonnet, Sandy Amorim, Christophe Fruchart, Roch Houot, Gian Matteo Pica, Carole Soussain, Sophie Dennetiere, Cécile Leyronnas, Pauline Lionne‐Huyghe, Hervé Ghesquières, Pierre Sesques   +29 more
wiley   +1 more source

BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

European Journal of Haematology, EarlyView.
ABSTRACT Objectives B‐cell maturation antigen (BCMA)‐targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real‐world impact within EMMY, a French longitudinal cohort. Methods Patients initiating a fourth or later line of therapy (L4+) between
Titouan Cazaubiel, Olivier Decaux, Aurore Perrot, Bruno Royer, Karim Belhadj‐Merzoug, Margaret Macro, Laure Vincent, Lionel Karlin, Arthur Bobin, Thomas Chalopin, Mohamad Mohty, Laurent Frenzel, Julie Gay, Cécile Sonntag, Jean Fontan, Olivier Allangba, Cyrille Touzeau, Hélène Demarquette, Jean‐Valère Malfuson, Claire Jouzier, Stéphane Darre, Benoit Bareau, Ariane Boumendil, Cyrille Hulin, on behalf of EMMY and the IFM group   +24 more
wiley   +1 more source

Dual-targeting VEGF and TNF-α with bispecific antibody eyedrops for synergistic treatment of uveitis. [PDF]

J Nanobiotechnology
Zhou J, Chen Y, Guan R, Cai W, Lin Z, Rao P, Chen S, Gao P, Yang Q, Wu Y, Zhu Y, Zhou B, Zhang N, Yang J, Chen X.   +14 more
europepmc   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Beyond resistance: optimizing CAR-T sequencing following bispecific antibody failure in DLBCL. [PDF]

J Transl Med
Zhang W, Fang Y, Gao S, Yao Y.
europepmc   +1 more source

Patient Preferences for the Treatment of Haemophilia A and B in France

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia impacts health and quality of life. Advances in treatments such as factor replacement therapy (FRT), bispecific monoclonal antibody (BS‐mAb), gene therapy (GT), rebalancing treatment and high sustained factor necessitate understanding patient preferences to inform therapeutic strategies. Aim This study quantified trade‐
Yesim Dargaud, Yasmine Fahfouhi, Monia Ezzalfani, Astrid Foix Colonier, Alaeddine Sidhom, Aline Gauthier, Jérémie Rudant, Meriem Kessouri, Nicolas Giraud, Benoît Guillet, Anaïs Reynaud   +10 more
wiley   +1 more source

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. [PDF]

Nat Med
Cohen AD, Richter J, Trudel S, Lesokhin A, Laubach JP, Thomas SK, Harrison SJ, Costa LJ, Spencer A, Fonseca R, Forsberg PA, Berdeja JG, Kaedbey R, Bahlis NJ, Rodriguez-Otero P, Mateos MV, Tyagi T, Samineni D, Liu W, Nakamura R, Choeurng V, Wong C, Cooper J, Krishnan A.   +23 more
europepmc   +1 more source